MD4793C1 - Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin - Google Patents

Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin Download PDF

Info

Publication number
MD4793C1
MD4793C1 MDA20160018A MD20160018A MD4793C1 MD 4793 C1 MD4793 C1 MD 4793C1 MD A20160018 A MDA20160018 A MD A20160018A MD 20160018 A MD20160018 A MD 20160018A MD 4793 C1 MD4793 C1 MD 4793C1
Authority
MD
Moldova
Prior art keywords
methyl
carbonyl
phenyl
tetrahydroisoquinoline
carboxamide
Prior art date
Application number
MDA20160018A
Other languages
English (en)
Romanian (ro)
Russian (ru)
Other versions
MD4793B1 (ro
MD20160018A2 (ro
Inventor
Джеймс Эдвард Пол Дэвидсон
Джеймс Брук МЮРРЕЙ
Ай-Джен ЧЕНЬ
Клэр Уолмсли
Марк ДОДСУОРТ
Йоханнес В.Г. МЕЙССНЕР
Пол БРОГ
Имре ФЕЕШ
Янош Татаи
Миклош Ньергеш
Андрас КОЦКИ
Золтан Славик
Оливье Женест
Тиран Арно Ле
Дигуарье Тьерри Ле
Жан-Мишель ХЕНЛИН
Жером-Бенуа Старк
Анна-Франсуаза ГИЙЮЗИС
Нантей Гийом Де
Original Assignee
Les Laboratoires Servier
Vernalis (R&D) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier, Vernalis (R&D) Limited filed Critical Les Laboratoires Servier
Publication of MD20160018A2 publication Critical patent/MD20160018A2/ro
Publication of MD4793B1 publication Critical patent/MD4793B1/ro
Publication of MD4793C1 publication Critical patent/MD4793C1/ro

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
MDA20160018A 2013-07-23 2014-07-22 Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin MD4793C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357276A FR3008977A1 (fr) 2013-07-23 2013-07-23 Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2014/065764 WO2015011164A1 (en) 2013-07-23 2014-07-22 New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them

Publications (3)

Publication Number Publication Date
MD20160018A2 MD20160018A2 (ro) 2016-07-31
MD4793B1 MD4793B1 (ro) 2022-02-28
MD4793C1 true MD4793C1 (ro) 2022-09-30

Family

ID=49911606

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20160018A MD4793C1 (ro) 2013-07-23 2014-07-22 Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin

Country Status (49)

Country Link
US (3) US9809574B2 (enExample)
EP (1) EP3024826B1 (enExample)
JP (1) JP6395829B2 (enExample)
KR (1) KR102008431B1 (enExample)
CN (2) CN109456324B (enExample)
AP (1) AP2016008989A0 (enExample)
AR (1) AR097009A1 (enExample)
AU (1) AU2014295101B2 (enExample)
BR (1) BR112016001080B1 (enExample)
CA (1) CA2919572C (enExample)
CL (1) CL2016000148A1 (enExample)
CR (1) CR20160030A (enExample)
CU (1) CU24352B1 (enExample)
CY (1) CY1121247T1 (enExample)
DK (1) DK3024826T3 (enExample)
DO (1) DOP2016000009A (enExample)
EA (1) EA032301B1 (enExample)
ES (1) ES2711371T3 (enExample)
FR (1) FR3008977A1 (enExample)
GE (1) GEP20207070B (enExample)
HK (1) HK1218754A1 (enExample)
HR (1) HRP20190277T1 (enExample)
HU (1) HUE041443T2 (enExample)
IL (1) IL243449A0 (enExample)
JO (1) JO3457B1 (enExample)
LT (1) LT3024826T (enExample)
MA (1) MA38801B1 (enExample)
MD (1) MD4793C1 (enExample)
ME (1) ME03346B (enExample)
MX (1) MX365373B (enExample)
MY (1) MY193619A (enExample)
NI (1) NI201600016A (enExample)
NZ (1) NZ716155A (enExample)
PE (1) PE20160241A1 (enExample)
PH (1) PH12016500034A1 (enExample)
PL (1) PL3024826T3 (enExample)
PT (1) PT3024826T (enExample)
RS (1) RS58344B1 (enExample)
RU (1) RU2689305C2 (enExample)
SA (1) SA516370439B1 (enExample)
SG (1) SG11201600205XA (enExample)
SI (1) SI3024826T1 (enExample)
TN (1) TN2016000003A1 (enExample)
TR (1) TR201819155T4 (enExample)
TW (1) TWI560184B (enExample)
UA (1) UA117490C2 (enExample)
UY (1) UY35664A (enExample)
WO (1) WO2015011164A1 (enExample)
ZA (1) ZA201600198B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112018071548A2 (pt) 2016-04-20 2019-04-16 Bristol-Myers Squibb Company compostos heterocíclicos bicíclicos substituídos
SG11202013026WA (en) 2018-06-27 2021-01-28 Proteostasis Therapeutics Inc Proteasome activity enhancing compounds
EP4059928A4 (en) * 2019-11-15 2023-11-15 Wuhan LL Science and Technology Development Co., Ltd. Rock inhibitor, preparation method therefor and use thereof
CN112010796B (zh) * 2020-09-17 2022-04-22 浙江大学 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法
EP4294513A1 (en) 2021-02-19 2023-12-27 Mevion Medical Systems, Inc. Gantry for a particle therapy system
AR125205A1 (es) * 2021-03-24 2023-06-21 Servier Lab Nuevo proceso para la síntesis de derivados del ácido 5-{5-cloro-2-[(3s)-3-[(morfolin-4-il)metil]-3,4-dihidroisoquinolina-2(1h)-carbonil]fenil}-1,2-dimetil-1h-pirrol-3-carboxílico y su aplicación para la producción de compuestos farmacéuticos
CN119053587A (zh) 2022-02-24 2024-11-29 法国施维雅药厂 5-[7-(3,4-二氢-1h-异喹啉-2-羰基)-1,2,3,4四氢异喹啉-6-基]-1h-吡咯-3-甲酰胺衍生物、含有其的药物组合物及其作为促细胞凋亡剂的用途
PE20251072A1 (es) 2022-05-20 2025-04-10 Novartis Ag Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos
CN121001985A (zh) * 2023-03-31 2025-11-21 三井化学株式会社 氨基甲酸酯化合物
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
TW202540185A (zh) 2023-11-22 2025-10-16 法商施維雅藥廠 抗cd74抗體藥物結合物及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093297A2 (en) 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
WO2004096774A1 (en) 2003-05-01 2004-11-11 Glaxo Group Limited Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
CN101039662A (zh) * 2004-08-20 2007-09-19 密执安州立大学董事会 抗-细胞凋亡bcl-2家族成员的小分子抑制剂及其应用
US8557812B2 (en) * 2004-08-20 2013-10-15 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
US20080227792A1 (en) * 2005-02-15 2008-09-18 Novo Nordisk A/S 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters
EP3243814B1 (en) 2007-04-16 2018-10-17 AbbVie Inc. 7-substituted indole as mcl-1 inhibitors
CN102007101A (zh) 2007-11-30 2011-04-06 生物区科学管理控股有限公司 作为抗菌剂的四氢-异喹啉ppat抑制剂
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ,インコーポレーテッド 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法
WO2009102463A2 (en) 2008-02-14 2009-08-20 Connor Reynolds Pet waste vacuum system and apparatus, disposable liners therefor, and a method of collecting pet waste using same
WO2012162365A1 (en) * 2011-05-25 2012-11-29 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
EP2794591A1 (en) * 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
EP2798432A4 (en) 2011-12-27 2015-07-22 Intel Corp METHODS AND SYSTEMS FOR CONTROLLING POWER SUPPLY NETWORKS DURING AN ACTIVE STATE OF A PERIODICALLY TRIGGERED DOMAIN IN ACCORDANCE WITH PERIODICALLY RELEASED DOMAIN LOADING CONDITIONS
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
JP2016525529A (ja) 2016-08-25
PL3024826T3 (pl) 2019-05-31
MX2016000904A (es) 2016-04-25
MY193619A (en) 2022-10-20
CA2919572A1 (en) 2015-01-29
ZA201600198B (en) 2019-07-31
CN109456324B (zh) 2022-04-22
MD4793B1 (ro) 2022-02-28
JO3457B1 (ar) 2020-07-05
PH12016500034B1 (en) 2016-03-28
TWI560184B (en) 2016-12-01
DOP2016000009A (es) 2016-03-15
DK3024826T3 (en) 2019-03-04
PH12016500034A1 (en) 2016-03-28
US20180002313A1 (en) 2018-01-04
MX365373B (es) 2019-05-31
MA38801A1 (fr) 2018-05-31
CA2919572C (en) 2017-06-20
EA032301B1 (ru) 2019-05-31
CN105431422A (zh) 2016-03-23
CN105431422B (zh) 2019-08-30
UA117490C2 (uk) 2018-08-10
BR112016001080B1 (pt) 2022-04-05
HUE041443T2 (hu) 2019-05-28
IL243449A0 (en) 2016-02-29
RU2689305C2 (ru) 2019-05-27
CU20160010A7 (es) 2016-06-29
US10689364B2 (en) 2020-06-23
RU2016106003A (ru) 2017-08-28
TW201504228A (zh) 2015-02-01
CR20160030A (es) 2016-03-09
AP2016008989A0 (en) 2016-01-31
HK1218754A1 (zh) 2017-03-10
EA201600122A1 (ru) 2016-07-29
HRP20190277T1 (hr) 2019-04-05
EP3024826A1 (en) 2016-06-01
JP6395829B2 (ja) 2018-09-26
EP3024826B1 (en) 2018-11-14
TR201819155T4 (tr) 2019-01-21
ES2711371T3 (es) 2019-05-03
CU24352B1 (es) 2018-07-05
CY1121247T1 (el) 2020-05-29
TN2016000003A1 (en) 2017-07-05
UY35664A (es) 2015-01-30
FR3008977A1 (fr) 2015-01-30
AU2014295101B2 (en) 2018-05-31
RS58344B1 (sr) 2019-03-29
MA38801B1 (fr) 2019-03-29
ME03346B (me) 2019-10-20
AU2014295101A1 (en) 2016-02-04
CN109456324A (zh) 2019-03-12
CL2016000148A1 (es) 2016-08-12
NI201600016A (es) 2016-02-11
NZ716155A (en) 2019-05-31
GEP20207070B (en) 2020-02-25
BR112016001080A2 (enExample) 2017-07-25
SI3024826T1 (sl) 2019-03-29
MD20160018A2 (ro) 2016-07-31
SG11201600205XA (en) 2016-02-26
HK1222856A1 (en) 2017-07-14
US9809574B2 (en) 2017-11-07
LT3024826T (lt) 2019-02-25
KR102008431B1 (ko) 2019-08-07
KR20160033224A (ko) 2016-03-25
AR097009A1 (es) 2016-02-10
US11028070B2 (en) 2021-06-08
SA516370439B1 (ar) 2019-06-27
US20200262816A1 (en) 2020-08-20
US20160194304A1 (en) 2016-07-07
WO2015011164A1 (en) 2015-01-29
PE20160241A1 (es) 2016-04-30
PT3024826T (pt) 2019-01-28

Similar Documents

Publication Publication Date Title
US11028070B2 (en) Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
US10662173B2 (en) Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
MD4575C1 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
MD4551C1 (ro) Derivaţi pe bază de tetrahidroizochinoline şi N-(fenilfosfat)amide, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
MD4643C1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
OA17896A (en) New compounds Isoindoline or Isoquinoline, process for their preparation and pharmaceutical compositions containing them.
NZ626623B (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
HK1222856B (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FG4A Patent for invention issued
HK9A Erratum in official gazette with regard to application (patent for invention)

Free format text: RECTIFICATION IN INID 13

TK4A Erratum in official gazette in regard to patent for invention

Free format text: RECTIFICATION IN INID 13

KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)